31st week of 2011 patent applcation highlights part 37 |
Patent application number | Title | Published |
20110189064 | PROCESSING BAG FOR COMPONENT SEPARATOR SYSTEM AND METHOD OF REMOVING SEPARATED COMPONENTS - A centrifugal processing bag, system and method for separating the components of a mixed material is presented. The processing bag includes a hub and a first port for receiving the mixed material, where the first port includes an outlet positioned within the processing bag at a perimeter of the bag. The processing bag also including a second port having a second port inlet spaced proximate the hub and away from a central axis of the hub. The second port directs a separated material collected from the second port inlet out of the processing bag. | 2011-08-04 |
20110189065 | INORGANIC DRY COMPOSITIONS FOR ABSORPTION OF MERCURY VAPOR - The present relates generally to inorganic dry compositions comprising inorganic salt impregnated substrates such as saturated bibulous matrices or non-bibulous coated surfaces allowing fabrication of materials of various shapes and kinds useful to suppress release of mercury vapor into the environment upon breakage of mercury containing lamp bulbs, and methods for the use thereof. | 2011-08-04 |
20110189066 | ROBUST MIXED CONDUCTING MEMBRANE STRUCTURE - The present invention provides a membrane, comprising in said order a first electronically conducting layer, an ionically conducting layer, and a second electronically conducting layer, | 2011-08-04 |
20110189067 | SORBENT FOR CARBON DIOXIDE - A sorbent for carbon dioxide is made by combining a strong alkaline material with an acidic material, and an adhesive medium. The components are mixed together, cut into pieces, and sieved. The resulting composition absorbs carbon dioxide from a gas stream, and can be regenerated by the application of steam. In the preferred embodiment, the alkaline material is calcium hydroxide, and the acidic material is potassium bisulfate. The ratio of the weight of the alkaline material to that of the acidic material, before mixing of the components, is preferably in the range of about 9-20. | 2011-08-04 |
20110189068 | SYSTEM FOR TREATING A GAS STREAM - A system for treating a gas stream containing nitrogen oxides (NO | 2011-08-04 |
20110189069 | EXHAUST GAS PURIFICATION CATALYST AND METHOD FOR PRODUCTION THEREOF - The invention realizes a catalyst which is hardly deteriorated even when volatile catalyst-poisoning compounds such as P and As are accumulated and which can reduce the rate of oxidation of SO | 2011-08-04 |
20110189070 | Method of Producing Amorphous Aluminum Silicate, Amorphous Aluminum Silicate Obtained with said Method, and Adsorbent using the same - The present invention aims to provide an adsorbent with superior adsorption performance of 20 wt % or more in a humidity range of 5 to 60 wt % by using a low-cost reagent as the raw material. Aluminum sulfate is used as the Al source, the respective aqueous solutions are mixed to achieve a Si/Al molar ratio of 0.70 to 1.0 in the mixed solution, the pH is adjusted to be 6 to 9 with acid or alkali, the solution is heated at 90 to 110° C. and subsequently subject to desalination treatment in order to synthesize an amorphous aluminum silicate. The obtained amorphous aluminum silicate yields a superior water vapor adsorption performance of 20 wt % or more in a relative humidity of 60%, and can be used as an adsorbent for desiccant air conditioning and as other adsorbents. | 2011-08-04 |
20110189071 | MESOPOROUS NANOSTRUCTURES - The invention provides a process for making a particulate mesoporous material. A solution comprising a surfactant and a base is combined with a hydrolysable precursor without agitating said solution. The resulting mixture is then allowed to stand without externally applied agitation for sufficient time for hydrolysis of the precursor to form the particulate mesoporous material. | 2011-08-04 |
20110189072 | PROCESS FOR PREPARING HIGHER HYDRIDOSILANES - Process for preparing higher hydridosilanes of the general formula H—(SiH | 2011-08-04 |
20110189073 | PROCESS FOR PURIFICATION OF MONOSILANE - Provided is a method of purifying monosilane. More particularly, the method includes removing impurities from a crude material containing monosilane and ethylene by fractional distillation (operation 1), and removing ethylene and residual impurities by passing the crude material purified in operation 1 through activated carbon (operation 2). According to the method, high-purity monosilane may be more simply and effectively obtained without additional production of byproducts by selectively adsorbing ethylene, which is difficult to separate by fractional distillation, using an activated carbon. | 2011-08-04 |
20110189074 | Silcon Production With A Fluidized Bed Reactor Integrated Into A Siemens-Type Process - A fluidized bed reactor and a Siemens reactor are used to produce polycrystalline silicon. The process includes feeding the vent gas from the Siemens reactor as a feed gas to the fluidized bed reactor. | 2011-08-04 |
20110189075 | LAMINAR FLOW AIR COLLECTOR WITH SOLID SORBENT MATERIALS FOR CAPTURING AMBIENT CO2 - The present disclosure provides a method for removing carbon dioxide from a gas stream without consuming excess energy, wherein a solid sorbent material is used to capture the carbon dioxide. The solid sorbent material may utilize a water-swing for regeneration. Various geometric configurations are disclosed for advantageous recovery of CO | 2011-08-04 |
20110189076 | SPHERICAL CARBON NANOSTRUCTURE AND METHOD FOR PRODUCING SPHERICAL CARBON NANOSTRUCTURES - A method for producing carbon nanostructures according to the invention includes injecting acetylene gas into a reactant liquid. The injected acetylene molecules are then maintained in contact with the reactant liquid for a period of time sufficient to break the carbon-hydrogen bonds in at least some of the acetylene molecules, and place the liberated carbon ions in an excited state. The liberated carbon ions in the excited state then traverse a surface of the reactant liquid and enter a collection area where carbon ions combine to produce carbon nanostructures. | 2011-08-04 |
20110189077 | MICROPOROUS GRAPHITE FOAM AND PROCESS FOR PRODUCING SAME - A microporous graphite foam, comprising a matrix of graphite fibers joined by a graphitized graphite-forming precursor, wherein the foam comprises irregular interstitial spaces having an average pore size in the range from about 0.1 to about 10 microns and a void fraction in the range from about 80% to about 95%. A process for producing a microporous graphite foam including a matrix of graphite fibers joined by a graphitized graphite-forming precursor. In its various embodiments, the graphite foam has one or more of pore sizes less than about ten microns, low bulk density, high physical strength and good machinability, while also having the desirable characteristics of graphite, including high thermal conductivity, electrical conductivity and solderability. A cryogenic cooling system including the graphite foam. In one embodiment, the graphite foam is a component of a cooling interface in the cryogenic cooling system. | 2011-08-04 |
20110189078 | APPARATUS AND METHOD FOR CONTINUOUS HIGH TEMPERATURE GAS TREATMENT OF PARTICULATE MATTER - An apparatus for continuous high temperature gas treatment of particulate matter including a starting material supply port ( | 2011-08-04 |
20110189079 | PROCESS FOR PRODUCING CHLORINE - Disclosed is a process for producing chlorine, which makes it possible to successfully continue an oxidation reaction, even if sulfur component-containing hydrogen chloride is used. This process comprises a step of feeding sulfur component-containing hydrogen chloride and oxygen into a reaction tube | 2011-08-04 |
20110189080 | Methods of making copper selenium precursor compositions with a targeted copper selenide content and precursor compositions and thin films resulting therefrom - Precursor compositions containing copper and selenium suitable for deposition on a substrate to form thin films suitable for semi-conductor applications. Methods of forming the precursor compositions using primary amine solvents and methods of forming the thin films wherein the selection of temperature and duration of heating controls the formation of a targeted species of copper selenide. | 2011-08-04 |
20110189081 | CRYSTALLINE INORGANIC SPECIES HAVING OPTIMISED REACTIVITY - A method for synthesizing high quality crystalline anatase titanium dioxide having a substantial occurrence of (001) facets. Including the steps of combining a source of fluoride anions with a titanium precursor and subjecting the mixture to hydrolysis. A solvent can be combined with the source of fluoride anions and the titanium precursor prior to hydrolysis. The crystalline anatase titanium dioxide can be produced to have the highly reactive (001) facets predominant by area in a variety of crystal structures, such as nanosheets. | 2011-08-04 |
20110189082 | HUMAN GM-CSF ANTIGEN BINDING PROTEINS - Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes. | 2011-08-04 |
20110189083 | Dock-and-Lock (DNL) Vaccines for Cancer Therapy - The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti-cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138 | 2011-08-04 |
20110189084 | Method for Treating Liver Disorders with Receptor Associated Protein (RAP) Peptide-Fucosidase Inhibitor Conjugates - The present invention relates, in general, to methods and compositions for the treatment of liver disorders and liver tumors, such as hepatocellular carcinoma, with a peptide of the receptor associated protein (RAP) molecule conjugated to a fucosidase inhibitor. | 2011-08-04 |
20110189085 | Antibody Therapy - The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition. | 2011-08-04 |
20110189086 | Diagnostic Method for Atherosclerosis - The invention relates to a method of identifying/monitoring active atherosclerotic plaques associated with blood vessel walls wherein the plaques comprise activated macrophages having accessible binding sites for a ligand. The method comprises the steps of administering to a patient being evaluated for atherosclerosis an effective amount of a composition comprising a conjugate of a ligand and a chromophore capable of emitting light under predetermined conditions, allowing sufficient time for the ligand conjugate to bind to the activated macrophages, subjecting the blood vessels to the predetermined conditions using a catheter-based device, and identifying active plaques by detecting light emitted by the chromophore using a catheter-based device or by using an external imaging technique. The invention also relates to a similar method wherein a chemical moiety capable of emitting radiation is conjugated to the ligand. | 2011-08-04 |
20110189087 | TMPRSS4-Specific Human Antibody - The present invention relates to a transmembrane protease, serine (TMPRSS4)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4-specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation. | 2011-08-04 |
20110189088 | RADIOPHARMACEUTICAL COMPLEXES - The invention provides compounds such as chelating agents useful in chelating metal ions, particularly radionuclides, to provide metal ion complexes. The invention also provides methods of using the compounds and complexes of the invention, such as in therapeutic and diagnostic applications. | 2011-08-04 |
20110189089 | RADIOFLUORINATION - The present invention relates to | 2011-08-04 |
20110189090 | MOLECULAR PROBES FOR IMAGING OF MYELIN - A molecular probe for labeling myelin includes a fluorescent trans-stilbene derivative. | 2011-08-04 |
20110189091 | COLON LAVAGE SYSTEM - The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion. | 2011-08-04 |
20110189092 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 2011-08-04 |
20110189093 | PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODIES AND ANTIGEN BINDING FRAGMENTS - Polypeptides, antibodies or antigen-binding fragments capable of binding to prostate specific membrane antigen (PSMA) are provided. These polypeptides, antibodies or antigen-binding fragments may be used for diagnostic and/or therapeutic purposes. | 2011-08-04 |
20110189094 | BIOLOGICAL METHOD FOR IN VIVO TRACKING OF MOLECULES AFFECTING CELLULAR MIGRATION - Cellular migration is a normal part of the normal development of the human being and, in certain pathologies, its alteration damages physiological performance, so that it is necessary to learn about its molecular and cellular foundations and establish methodologies to identify those molecules that modulate this cellular behavior. A screening method using zebra fish embryos is used to follow the advance in the migration of the lateral line primordium upon contact with a test compound. Modulators N found are Fenritinide, PGD2 and is-deoxy-PJE2. The invention refers to a biological method for the IN VIVO, fast, massive and simultaneous tracking of molecules capable of affecting cellular migration, in order to facilitate the for of potential candidates to be used in the diagnosis, prevention, and, principally, for the preparation of pharmaceutical compositions for the treatment of congenital pathologies, immune system dysfunctions, tissue regeneration failure, inflammation, cancer. | 2011-08-04 |
20110189095 | CRKL TARGETING PEPTIDES - Provided are methods and compositions for selectively targeting CRKL through the use of targeting peptides. Selective targeting of secreted CRKL through the use of a targeting peptide may be used, for example, in the treatment of cancer to deliver a chemotherapeutic compound, fusion protein, or fusion construct to a cancer cell or tissue. | 2011-08-04 |
20110189096 | CENTRAL NERVOUS SYSTEM TISSUE-LABELING COMPOSITION, METHOD FOR LABELING CENTRAL NERVOUS SYSTEM TISSUE, AND SCREENING METHOD USING CENTRAL NERVOUS SYSTEM TISSUE-LABELING COMPOSITION - To provide a central nervous system tissue-labeling composition labeling the central nervous tissue system. Also, another object of the present invention is to provide a method for non-invasively labeling the central nervous tissue system. Further, another object of the present invention is to provide a screening method using the above central nervous system tissue-labeling composition. A central nervous system tissue-labeling composition containing, as an active ingredient, at least one of compounds represented by the general formula (1) or (7). | 2011-08-04 |
20110189097 | Use of WNT inhibitor to inhibit angiogenesis in the CNS - Activation of the Wnt signaling pathway in cells is inhibited by contacting the cells with an Apcdd peptide. Wnt inhibition by this and other methods finds particular use in treating Wnt-mediated disease conditions such as conditions associated with aberrant angiogenesis in the CNS or aberrant cell proliferation. | 2011-08-04 |
20110189098 | THERAPY DELIVERY AND MONITORING USING A GENE OF INTEREST-REPORTER FUSION PROTEIN AND OPTICAL IMAGING - The present invention relates to a method of non-invasively monitoring the expression of a gene of interest in a cell when contacting said cell with a compound influencing the expression of said gene of interest. The present invention is also concerned with different isolated nucleic acid molecules comprising a coding sequence. Said coding sequence comprises a gene of interest-sequence encoding a gene of interest-polypeptide fused to a reporter sequence encoding a fluorescent reporter polypeptide and is operatively coupled to a promoter sequence. The present invention is also concerned with the use of a method and a nucleic acid molecule of the invention for delivering a compound influencing the expression of a gene of interest in a cell, monitoring the delivery of said compound as well as monitoring the influence on the expression of said gene fluorescence of interest induced by said compound at the same time. | 2011-08-04 |
20110189099 | ATTENUATED MYCOPLASMA GALLISEPTICUM STRAINS - The present invention provides live, attenuated | 2011-08-04 |
20110189100 | BONE SUBSTITUTE CONTAINING A CONTRAST AGENT, METHOD FOR PREPARING SAME AND USES THEREOF - The invention relates to a composition for biomaterials, characterised in that it comprises a calcium phosphate, in which the molar ratio Ca/P is 1 to 2, sintered with a medical imaging contrast agent uniformly distributed in the composition mass. The invention also relates to a method for preparing the same and to the medical uses thereof. | 2011-08-04 |
20110189101 | FLUORESCENT LABELING AGENT AND FLUORESCENT LABELING METHOD - Disclosed is use of zinc oxide nanoparticles as an exciton emission source in vivo or in vitro. Also disclosed is a fluorescent labeling agent comprising a zinc oxide nanoparticle and a substance capable of selectively binding to a target in vivo or in vitro, wherein the substance is bound to the zinc oxide nanoparticle via at least one binder. Further disclosed is a fluorescent labeling agent comprising a zinc oxide nanoparticle of which the surface is coated with a coating film selected from ZnS, Mg | 2011-08-04 |
20110189102 | COATED QUANTUM DOTS AND METHODS OF MAKING AND USING THEREOF - The present disclosure provides embodiments of a new class of hydroxylated quantum dots. The quantum dots have a hydroxylated coat disposed thereon, and which serves to minimize non-specific cellular binding and to maintain the small size of quantum dot probes. Embodiments of the coated quantum dots of the disclosure are just slightly larger than the diameter of uncoated quantum dots, and are bright with high quantum yields. They are also very stable under both basic and acidic conditions. Embodiments of the hydroxylated quantum dots result in significant reductions in non-specific binding relative to that of carboxylated dots, and to protein and PEG-coated dots. Embodiments of the disclosure are advantageous in a range of biological applications where non-specific binding is a major problem, such as in multiplexed biomarker staining in cells and tissues, detection of biomarkers in body fluid samples (blood, urine, etc.), as well as live cell imaging. | 2011-08-04 |
20110189103 | Aerosolized Fosfomycin/Aminoglycoside Combination for the Treatment of Bacterial Respiratory Infections - A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler. | 2011-08-04 |
20110189104 | SURFACTANT PROTEIN D FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH LUNG INJURY - Surfactant protein D (SP-D) is a 43-kDa member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD) using recombinant human surfactant protein D and surfactant formulations. | 2011-08-04 |
20110189105 | GRIFFITHSIN, GLYCOSYLATION-RESISTANT GRIFFITHSIN, AND RELATED CONJUGATES, COMPOSITIONS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCTION AND METHODS OF USE - An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, and, when the at least eight contiguous amino acids comprise amino acids 1-121 of SEQ ID NO: 3, the at least eight contiguous amino acids have been rendered glycosylation-resistant, a vector comprising such an isolated and purified nucleic acid molecule, a host cell comprising the nucleic acid molecule, optionally in the form of a vector, a method of producing an anti-viral polypeptide or conjugate thereof, the anti-viral polypeptide itself, a conjugate or fusion protein comprising the anti-viral polypeptide, and compositions comprising an effective amount of the anti-viral polypeptide or conjugate or fusion protein thereof. Further provided are methods of inhibiting prophylactically or therapeutically a viral infection of a host. | 2011-08-04 |
20110189106 | INTRANASAL COMPOSITIONS, DOSAGE FORMS AND METHODS OF TREATMENT - Various embodiments of the present invention provide for compositions, dosage forms and methods useful in treating, relieving or prophylactically treating of one or more symptom of an allergic and/or inflammatory condition. | 2011-08-04 |
20110189107 | ALPHA-AMYLASE INHIBITORS: THE MONTBRETINS AND USES THEREOF - Particular naturally occurring glycosylated acyl-flavonols, e.g. montbretin A (of the formula below wherein R | 2011-08-04 |
20110189108 | USE OF 1-(2,4-DIHYDROXY-PHENYL)-3-(3-HYDROXY-4-METHOXY-PHENYL)-PROPAN-1-ON- E - The invention concerns the use of a
| 2011-08-04 |
20110189109 | COMPOSITIONS COMPRISING FENUGREEK HYDROCOLLOIDS - The present invention discloses compositions comprising fenugreek hydrocolloids comprising soluble and insoluble dietary fibers. The present invention further relates to the use of these compositions comprising fenugreek hydrocolloids as healthcare, personal care, food, household care and industrial products. | 2011-08-04 |
20110189110 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF XEROSTOMIA - The present invention is directed to methods and compositions comprising a basic amino acid, e.g., arginine, for the treatment of dry mouth. | 2011-08-04 |
20110189111 | Novel Composition - A dentifrice composition comprising a source of fluoride ions and from 0.01-1.5% w/w of a xanthan gum, from 0.01-1.5% w/w of a polyacrylic acid, from 0.01-2.0% w/w of a carageenan gum and a thickening silica and wherein the composition has a pH of between 5.5 and 6.5. | 2011-08-04 |
20110189112 | Additives for Chlorine Dioxide-Containing Compositions - Provided is a composition containing chlorine dioxide, a vehicle and at least one compatible additive. The composition optionally contains a compatible amount of a non-compatible additive. Methods of making and using the composition are also provided. | 2011-08-04 |
20110189113 | Water-Resistant, Rub-Resistant, Sprayable Homogeneous Sunscreen Composition - In accordance with the present invention, there is provided a water-resistant, rub-resistant, sprayable, clear, and homogeneous sunscreen composition which includes an active sunscreen ingredient, alcohol, and a vinyl lactam or maleimide polymer soluble in the composition. | 2011-08-04 |
20110189114 | MINOXIDIL COMPOSITION AND NON-AEROSOL, NON-SPRAY FOAM METHOD OF DELIVERY THEREFOR - A foamable composition is described that contains one or more of: minoxidil, or a pharmaceutically acceptable salt thereof, an aqueous-alcoholic solvent medium which enables said minoxidil or said pharmaceutically acceptable salt thereof to be solubilized, a surfactant, such as oleth-20, a foam stabilizer, such as lauryl glucoside, and a sunscreen. The foamable minoxidil composition is optionally delivered in a measured dosage as a foam using a non-pressurized container, where the foam is produced within the container without use of a propellant. | 2011-08-04 |
20110189115 | METHOD AND APPARATUS FOR DELIVERY OF A MEASURED DOSAGE OF A NON-AEROSOL, NON-SPRAY FOAM COMPOSITION OF MINOXIDIL - A non-pressurized container that contains one or more of: a foamable composition of minoxidil, or a pharmaceutically acceptable salt thereof, an aqueous-alcoholic solvent medium which enables said minoxidil or said pharmaceutically acceptable salt thereof to be solubilized, a surfactant, such as oleth-20, a foam stabilizer, such as lauryl glucoside, and a sunscreen. The foamable minoxidil composition is optionally delivered in a measured dosage as a foam using a non-pressurized container, where the foam is produced within the container without use of a propellant. | 2011-08-04 |
20110189116 | HAIR TREATMENT METHODS - A method of colouring a material, the method comprising the steps of: a)applying to the material a composition comprising a sulphur-containing nucleophile; and b)applying to the material a composition comprising a dye compound selected from a dye class other than the class of reactive dyes. | 2011-08-04 |
20110189117 | COSMETIC COMPOSITION CONTAINING A POLYORGANISILOXANE POLYMER - The invention relates to a physiologically acceptable composition, especially a cosmetic composition, comprising at least one polyorganosiloxane containing polymer comprising at least one moiety which comprises: at least one polyorganosiloxane group consisting of 1 to about 1000 organosiloxane units in the chain of the moiety or in the form of graft, and at least two groups capable of establishing hydrogen interactions. | 2011-08-04 |
20110189118 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, AND COMPOUND - The invention relates to a cosmetic composition, particularly for hair care, and to a method for cosmetically treating keratin material, particularly the hair, using the compounds of Formula (I), where: —n=1, 2, 3, or 4; —R1, R′1, R2, and R′2 are H, —OH, —NRR′, or a C1-C18 carbon group capable of containing one or more heteroatoms selected from among O, S, and N; and —Z is a multivalent carbon radical optionally substitutable and/or interruptible by specific groupings, it being understood that said radical Z includes at least one heteroatom selected from among N, O, and S. | 2011-08-04 |
20110189119 | COMPOSITION FOR PERMANENT WAVE - Disclosed is a low-irritant, high-performance composition for permanent waves. It comprises L-cysteine or a mixture of L-cysteine and L-acetylcysteine as a reducing agent, for breaking disulfide bridges of cystines to form cysteines; L-arginine for swelling keratin fibers to facilitate deep invasion of the reducing agent into the keratin fibers; and a citrus peel powder or extract, containing peptides for promoting growth of dermal papilla cells and D-limonene for preventing depilation, and optionally with histidine for regenerating the hair, a powder or extract of green tea leaves for exerting an astringent effect on a scalp, chlorella for exerting an anti-bacterial and deodorizing effect on the scalp, a powder or extract of cactus for preventing a horny tissue from being generated on the scalp or desquamating upper layers of dead skin cells from the scalp, and polyquaternium or Hydroxyethylcellulose as a viscosity-inducing substance, whereby the human hair can be healthily changed from waves to straight or vice versa within a short time without irritation to the skin and the scalp and the formed curls can be prolonged with elasticity. | 2011-08-04 |
20110189120 | AEGYPTIN AND USES THEREOF - The present invention relates to the discovery of the Aegyptin gene and Aegyptin protein, a molecule that interacts with collagen and inhibits platelet adhesion, activation and aggregation. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed. | 2011-08-04 |
20110189121 | BITABLETS COMPRISING COMPACTED POLYALLYLAMINE POLYMER AND METHOD FOR THE PRODUCTION THEREOF - The invention relates to a method for producing tablets comprising a polyallylamine polymer, comprising the steps (i) preparation of a polyallylamine polymer or pharmaceutically compatible salts thereof, optionally in a mixture with one or more pharmaceutical excipients; (ii) compaction to give a slug; (iii) granulation of the slug; and (iv) compression of the resulting granules to give tablets; and also to tablets, sachets and slugs comprising a compacted polyallylamine polymer. In addition, the invention relates to tablets comprising a polyallylamine polymer, in particular Sevelamer, with a bimodal pore size distribution. | 2011-08-04 |
20110189122 | Use of Molt-Accelerating Compounds, Ecdysteroids, Analogs Thereof, and Chitin Synthesis Inhibitors for Controlling Termites - The subject invention relates in part to the oral administration of ecdysteroids for controlling subterranean termites. Preferred ecdysteroids for use according to the subject invention are ecdysone, certain ecdysone analogs, and 20-hydroxyecdysone, for example. In some preferred embodiments, one or more of these compounds is used in a termite bait in combination with one or more chitin synthesis inhibitors. Thus, the subject invention also relates in part to controlling termites by the use of a chitin synthesis inhibitor (CSI), such as hexaflumuron and/or noviflumuron, together with an ecdysteroid (and analogs thereof) or molt-accelerating compound (MAC), such as halofenozide. The subject invention also relates to mixtures comprising these two active ingredients. The MAC/ecdysteroid analog induces a preliminary molting event in termite workers (they could not complete the molting), which then allows the CSI to further disrupt the molt and cause mortality. The combination of these active ingredients, causing accelerated molting together with inhibition of chitin synthesis surprisingly shown herein to enhance activity against termites, as compared to either group of compounds alone. | 2011-08-04 |
20110189123 | MAMMALIAN CX3C CHEMOKINE ANTIBODIES - Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided. | 2011-08-04 |
20110189124 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES - The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins. | 2011-08-04 |
20110189125 | Modulators of HSP70/DnaK Function and Methods of Use Thereof - Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed. | 2011-08-04 |
20110189126 | COMPOSITIONS CONTAINING INTERLEUKIN-1 AND PEPTIDES - The present invention relates to pharmaceutical, dermatological, cosmeceutical, or cosmetic compositions comprising (a) interleukin-1 family members consisting of interleukin-1 alpha, interleukin-1 family member 5 (delta), interleukin-1 family member 6 (epsilon), interleukin-1 family member 7 (zeta), interleukin-1 family member 8 (eta), interleukin-1 family member 9, interleukin-1 family member 10 (theta), and interleukin-18; (b) a peptide of the general formula (I): Tyr-X | 2011-08-04 |
20110189127 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Tricyclic Indole Derivatives, compositions comprising at least one Tricyclic Indole Derivatives, and methods of using the Tricyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 2011-08-04 |
20110189128 | RECOMBINANT SUPER-COMPOUND INTERFERON - This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers. This invention also provides an artificial gene which codes for the super-compound interferon or its equivalent. Finally, this invention provides methods to produce recombinant super-compound interferon or its equivalent and various uses of said interferon. | 2011-08-04 |
20110189129 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2011-08-04 |
20110189130 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES - The invention relates to compounds of a general formula (I): | 2011-08-04 |
20110189131 | ACTIVE VARIANTS OF THE IL-18 BINDING PROTEIN AND MEDICAL USES THEREOF - The invention relates to active fragments of the IL-18 binding protein, to pharmaceutical compositions comprising such active fragments, and to medical uses thereof. | 2011-08-04 |
20110189132 | MICROBIAL PRODUCT CONTAINING MULTIPLE MICROORGANISMS - Methods to reduce or inhibit populations of pathogenic bacteria in animals are disclosed. These methods include providing a number of administrations of probiotic microorganism compositions containing one or more strains or species of probiotic microorganisms. Routes of administration, dosage of administration and pathogenic organisms to be reduced or inhibited are also disclosed. | 2011-08-04 |
20110189133 | SKIN TREATMENT COMPOSITIONS - This invention relates to | 2011-08-04 |
20110189134 | FERMENTATION PRODUCT CONTAINING EQUOL-PRODUCING MICROORGANISM HAVING MAINTAINED EQUOL-PRODUCING ABILITY, AND METHOD FOR PRODUCING SAME - An object of the present invention is to provide a fermented product containing equol-producing microorganisms in the state of living cells by which equol production ability is maintained. | 2011-08-04 |
20110189135 | HUMAN STEM CELL-DERIVED NEURAL PRECURSORS FOR TREATMENT OF AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM - The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of CNS autoimmune diseases, or for the preparation of a pharmaceutical composition for treating CNS autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of CNS autoimmune diseases. A preferred autoimmune disease in the context of the present invention is multiple sclerosis where the population of cells is administered to the CNS for local treatment of the disease. | 2011-08-04 |
20110189136 | USES AND ISOLATION OF VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS - The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject. | 2011-08-04 |
20110189137 | METHOD FOR GENERATION AND REGULATION OF IPS CELLS AND COMPOSITIONS THEREOF - The present invention provides methods for generating induced pluripotent stem (iPS) cells having an increased efficiency of induction as compared with conventional methods. The method includes treating a somatic cell with a nuclear reprogramming factor in combination with an agent that alters microRNA levels or activity in the cell and/or a p21 inhibitor. The invention further provides iPS cells generated by such methods, as well as clinical and research uses for such iPS cells. | 2011-08-04 |
20110189138 | REPAIR AND/OR RECONSTITUTION OF INVERTEBRAL DISCS - This invention relates to a method for repair and reconstitution of invertebral discs in a subject which involves administration of STRO-1 | 2011-08-04 |
20110189139 | Hematopoietic Cell E-Selectin/L-Selectin Ligand Glycosylated CD44 Polypeptide - The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal. | 2011-08-04 |
20110189140 | Compositions and Methods for Tissue Repair with Extracellular Matrices - Described herein are compositions comprising decellularized cardiac extracellular matrix and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, damaged or ischemic cells, tissues or organs in a subject, preferably a human, using a decellularized cardiac extracellular matrix of the invention are provided. Methods of preparing cardiomyocyte culture surfaces and culturing cells with absorbed decellularized cardiac extracellular matrix are provided. | 2011-08-04 |
20110189141 | MULTIPLE TARGET T CELL RECEPTOR - The present invention is directed to a functional T cell receptor (TCR) fusion protein (TFP) recognizing and binding to at least one MHC-presented epitope, and containing at least one amino acid sequence recognizing and binding an antigen. The present invention is further directed to an isolated nucleic acid molecule encoding the same, a T cell expressing said TFP, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen. | 2011-08-04 |
20110189142 | Senescene Cells and Methods For Its Production - The present invention relates to a method for the generation of immortalized transduced cell lines susceptible to senescence whereby the senescence is exogenously inducible and said cells can switch severalfold between the senescent stage and the immortalized stage. In particular, the present invention relates to a method for the generation of immortalized transduced cell lines susceptible to senescence wherein two or more different immortalizing gene sequences have been incorporated whereby said immortalizing gene sequences are regulated by regulators controlled via exogenous means. In a further aspect, the present invention relates to immortalized transduced cell lines obtainable with said method. In addition, methods for screening molecules influencing senescence of cells are provided as well as kits for conducting the same. | 2011-08-04 |
20110189143 | FORMULATION AND METHOD FOR TREATING PLANTS TO CONTROL OR SUPPRESS A PLANT PATHOGEN - The present invention provides formulations and methods for preventing, suppressing, treating, or controlling pre- or post-harvest disease or decay in plants. In the inventive method, plants are contacted with a formulation including an antagonistic microorganism and a booster composition. The booster composition generally includes about 3 parts Kaolin clay, about 1 part yeast, about 1 part Yucca plant extract, and about 1 part calcium-source material. The antagonistic microorganism may be included in an amount of between about 0.02 parts and about 0.5 parts by weight of the formulation, with about 0.04 parts antagonistic microorganism being preferred in testing to date. The formulation is typically applied to the above ground structures of the plant, including its leaves, flowers, stems, trunk, blossoms and fruit. | 2011-08-04 |
20110189144 | Compositions Comprising Lactobacillus Casei for Improving Resistance to Common Infectious Diseases - The use of a | 2011-08-04 |
20110189145 | Inhibition of Pathogens by Probiotic Bacteria - Compositions containing a lactic acid-producing bacterial strain, e.g., | 2011-08-04 |
20110189146 | Methods of Use of Probiotic Lactobacilli for Companion Animals - According to the present invention there are provided methods of use in companion animals of probiotic bacteria of the genus | 2011-08-04 |
20110189147 | PROCESS AND COMPOSITION FOR THE MANUFACTURE OF A MICROBIAL-BASED PRODUCT - Processes to produce microorganisms that can be incorporated into a microbial-based product that results in high viable cell yields and shelf-stable products are disclosed. These microbial-based products are useful for inhibiting pathogenic growth and as a food additive. A preferred microorganism is a lactic acid producing bacteria. In one embodiment, the process comprises inoculating a | 2011-08-04 |
20110189148 | LACTOSE COMPOSITIONS WITH DECREASED LACTOSE CONTENT - The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to an individual a lactose composition with decreased lactose content in combination with effective amounts of prebiotics and/or probiotics. | 2011-08-04 |
20110189149 | New Uses of Lactic Acid Bacteria and Bifidobacteria - The invention comprises use of a bacterium selected from a lactic acid bacterium, a | 2011-08-04 |
20110189150 | TANGENTIAL FLOW FILTRATION DEVICES AND METHODS FOR LEUKOCYTE ENRICHMENT - The present invention provides tangential flow filtration devices and methods for enriching a heterogenous mixture of blood constituents for leukocytes by removal of non-leukocyte blood constituents. In one particular embodiment the device can provide a composition enriched in monocytes. | 2011-08-04 |
20110189151 | COMPOSITIONS AND METHODS FOR PROLONGING SURVIVAL OF PLATELETS - The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis. | 2011-08-04 |
20110189152 | Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency - A combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases. | 2011-08-04 |
20110189153 | Compositions and Methods for Treating Collagen-Mediated Diseases - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 2011-08-04 |
20110189154 | Applications For A New Class Of Enzymes: Sulfiredoxins - Applications of a new class of enzymes, sulfiredoxines (Srx), catalyzing the reduction of Cys-SO | 2011-08-04 |
20110189155 | Large Form Of Human 2',5'-Oligoadenylate Synthetase OAS3 for Preventing or Treating Infection With Positive-Sense Single-Stranded RNA Viruses - Use of the large form of human 2′,5′-Oligoadenylate Synthetase (OAS3) for diagnosis, prevention and treatment of infection with positive-sense single-stranded RNA viruses and for prediction of human genetic susceptibility to positive-sense single-stranded RNA virus-related diseases. | 2011-08-04 |
20110189156 | Method for Treating Systemic Bacterial, Fungal and Protozoan Infection - A treatment for the diseases that are accompanied by quantitative and qualitative changes of blood extracellular DNA and, more particularly, to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method consist from introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa when said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNASE enzyme: said agent must be administered in doses and regimens which sufficient to decrease number average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease of number average molecular weight might be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient. A DNASE enzyme may be further applied in a dose and regime that provide a DNA hydrolytic activity measured in blood plasma exceeding 1.5 Kunitz units per 1 ml of blood plasma for more than 12 hours within a period of 24 hours. | 2011-08-04 |
20110189157 | USE OF HUMAN HYALURONIDASES FOR AXONAL REGROWTH - Chondroitin sulfate proteoglycans (CS-PGs) are axon growth inhibitory molecules present in the glial scar that are responsible (at least in part) for regeneration failure after CNS or spinal cord injury. Removal of chondroitin sulfate glycosamino-glycan chains using the bacterial enzymes chondroitinase-ABC or AC in models of CNS injury promotes both axon regeneration and plasticity. The present invention relates to the use of members of the human hyaluronidase family (endo-beta-acetyl-hexosaminidase enzymes, E.C. 3.2.1.35) for the degradation of chondroitin sulfate (proteoglycans) in the glial scar to promote axonal regrowth in human CNS or spinal cord injury. The present invention also relates to methods for determining endoglycosidase activity, and in particular of the hyaluronidase/chondroitinase type, in a sample, and also relates to methods for detecting compounds that modulate the activity of endoglycosidases and in particular endoglycosidases of the hyaluronidase/chondroitinase type. | 2011-08-04 |
20110189158 | CLOSTRIDIAL NEUROTOXINS WITH ALTERED PERSISTENCY - The invention relates to a polypeptide comprising:
| 2011-08-04 |
20110189159 | METHODS AND COMPOSITIONS FOR PROTEIN DELIVERY - The present invention provides methods and compositions for protein delivery. The invention features virus like particles, methods of making virus like particles and methods of using virus like particles to deliver proteins to a cell, to provide protein therapy and to treat diseases or disorders. The invention also features methods of targeting a protein to a cell, methods of protein therapy and methods of treating diseases or disorders using a TUS protein, a NLS or NES identified from full length TUS. | 2011-08-04 |
20110189160 | Veterinary Topical Agent - Methods and compositions for treating skin conditions in animals, which tend to have higher skin pH than humans, including wounds, ulcers, rashes, burns, abrasions, and other irritations and relevant injuries are provided. The invention contemplates the use of an aqueous or emollient medium having non-occlusive properties with one or more pH raising ingredients in a composition specifically designed to deliver oxygen to the skin's surface. | 2011-08-04 |
20110189161 | NUTRIGENOMICS METHODS AND COMPOSITIONS - The present invention provides a proprietary compositions and systems to modulate genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and prognosis, as well as the metabolism, efficacy and/or toxicity associated with specific vitamins, minerals, herbal supplements, homeopathic ingredients, and other ingredients for the purposes of customizing a subject's nutritional supplement formulation to optimize specific health outcomes. Specific to this invention the utilization of certain known polymorphic genes associated with Substance Use Disorder (SUD) are analyzed to target certain genetic anomalies that lead to a high risk and predisposition to SUD. The genotypic patterns are then utilized to provide certain nutritional customized solutions especially related to the attenuation of aberrant abuse of physician prescribed narcotic pain medication across all pain conditions. A priority GENOPROFILE is measured and directs the customization of a subsequent nutraceutical to act as a therapeutic modality. Specifically the treatment includes slow attenuation of the pain medication by incorporating orals (shakes, liquid beverages, pills, tablets, troche, ointments etc.), Intramuscular, Intravenous, intra-rectal and any form necessary to deliver a sufficient amount of an anti-craving and anti-stress nutraceutical. Moreover, the invention includes examples of novel analgesic ointments coupling Synaptamine and such analgesic and other anesthetic compounds including but not limited to Gabapentin, Ketamine, Baclofen, Ketoprofen, Amitriptyline, Lidocaine, Cyclobenzapine, Diclofenac, Menthol, Camphor and Capsaicin. The GENOPROFILE will be used to determine pain sensitivity Intolerance. | 2011-08-04 |
20110189162 | Modified Clostridial Toxins Comprising an Integrated Protease Cleavage Site-Binding Domain - The present specification discloses modified Clostridial toxins, compositions comprising an integrated protease cleavage site-binding domain, polynucleotide molecules encoding such modified Clostridial toxins and compositions comprising di-chain forms of such modified Clostridial toxins. | 2011-08-04 |
20110189163 | Compositions and Methods for Treating Collagen-Mediated Diseases - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 2011-08-04 |